The Pharma Data

JANUARY 17, 2021

plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields. SEOUL, South Korea , Jan. FDA this year.

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

Metabolite Tales Blog

NOVEMBER 17, 2022

Roquinimex (Linomide), a drug developed by Pfizer for the treatment of multiple sclerosis, is structurally related to laquinimod. Now that the former company has discontinued development of laquinimod for multiple sclerosis, the latter company is pursuing laquinimod as a treatment for non-infectious uveitis ( [link] ).

International 52

International Licensing Licensing Treatment 52

The Pharma Data

JANUARY 20, 2021

21, 2021 /PRNewswire/ — Dynacure , a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today the appointment of Jean M. View original content to download multimedia: [link]. ” Ms.

Treatment 52

Treatment Pharmaceuticals Drug Development Science 52

Perficient: Drug Development

DECEMBER 31, 2023

Integrating with Professional Treatment Strengthening the Support System Moodpath isn’t designed to replace professional treatment but to complement it. This integration aims to bridge gaps, ensuring a more holistic and personalized treatment plan.

Treatment 52

Treatment Production 52

Perficient: Drug Development

NOVEMBER 15, 2023

Missing doses or taking medications at irregular intervals can compromise the effectiveness of treatment, leading to increased seizure activity and other health complications. This feature helps individuals and their healthcare providers monitor adherence and make informed decisions about treatment plans.

Pharmacy 52

Pharmacy Treatment Production Drugs 52

The Pharma Data

DECEMBER 28, 2020

Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Annamycin for treatment of soft tissue sarcomas. .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

JANUARY 13, 2021

14, 2021 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow , an accomplished pharmaceutical executive, as Chief Development Officer. We are excited to attract such top tier talent from the psychedelic drug development community.

Clinical Trials 52

Clinical Trials FDA Trials Production 52

The Pharma Data

DECEMBER 28, 2020

Dr Reimer will replace Dr Charlotte Russel and be overall medically responsible for Alligator’s drug development candidates, with an emphasis on bringing mitazalimab and ATOR-1017 into Phase II efficacy studies. The following files are available for download: View original content: [link]. SOURCE Alligator Bioscience.

Clinical Development 52

Clinical Development Doctors Drug Development International 52

Perficient: Drug Development

NOVEMBER 30, 2023

This data can be instrumental in refining treatment plans and understanding the frequency and triggers of seizures. Data Logging and Analysis Advanced alert systems often include data logging capabilities, allowing users and healthcare professionals to track seizure patterns over time.

Production 52

Production Treatment 52

The Pharma Data

OCTOBER 16, 2020

Novan has been evaluating the ability of its NITRICIL platform technology as a potential nasal treatment option for Covid-19, announcing its potential efficacy as an antiviral against SARS-CoV-2, the virus that causes Covid-19. In vitro antiviral technology proves effective against SARS-CoV-2 in human airway infection model.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Clinical Research 52

The Pharma Data

NOVEMBER 10, 2020

Dr. Liu shared his over 30 years of R&D experience in drug development both in the global pharmaceutical companies and world renowned scientific research institutions. By joining Innovent, Dr. Liu will be responsible for global R & D, pipeline strategy, business development and international operations.

Biosimilars 52

Biosimilars Clinical Trials International Clinical Development 52

Perficient: Drug Development

NOVEMBER 15, 2023

Apps and reminders help users keep track of medication schedules, ensuring adherence to prescribed treatment plans and reducing the risk of missed doses. Medication Management Tools: Technology has simplified medication management for individuals with seizure disabilities.

Production 52

Production Treatment Marketing 52

The Pharma Data

JANUARY 27, 2021

. “The responses observed in six out of nine patients are very encouraging and clearly suggest that BI-1206 may restore the response to rituximab in patients who have few treatment alternatives. ET ) to discuss the results and next steps in clinical development of BI-1206. CEO of BioInvent.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

Perficient: Drug Development

JUNE 30, 2023

While this model has played a significant role in providing medical care and treatments, it has faced criticism for overlooking the social and environmental factors that contribute to disability and for pathologizing individuals with disabilities.

Treatment 52

Treatment Production Marketing 52

The Pharma Data

JANUARY 10, 2021

Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to evaluate IDE397, a small molecule methionine adenosyltransferase 2a (MAT2A) inhibitor, for the treatment of patients having solid tumors with methylthioadenosine phosphorylase (MTAP) deletion. View original content to download multimedia: [link].

FDA 52

FDA Small Molecule Clinical Trials Therapies 52

The Pharma Data

OCTOBER 19, 2020

Caris’ collaborative network focused on expanding the application of precision medicine in oncology supports Winship’s enterprising approach to research leading to transformative discoveries in cancer care and treatment. IRVING, Texas and ATLANTA , Oct. Winship is one of 32 U.S. Ramalingam , M.D.,

Clinical Trials 52

Clinical Trials RNA DNA Science 52

The Pharma Data

DECEMBER 14, 2020

The global GBM treatment market is projected to reach $3.3 The ability of a drug candidate to cross the blood brain barrier is of critical importance in treatment outcomes for CNS and brain cancers. Many drugs fail in clinical trials because of their low blood brain barrier permeability. .

Clinical Trials 52

Clinical Trials DNA Drugs Therapies 52

Perficient: Drug Development

NOVEMBER 15, 2023

This data can be valuable for healthcare professionals in adjusting treatment plans and understanding the individual’s unique seizure patterns. It enables a more informed approach to treatment, allowing for adjustments and personalized care plans based on the individual’s unique seizure patterns.

Treatment 52

Treatment Production 52

Perficient: Drug Development

OCTOBER 16, 2023

Medication Management: Challenges in adhering to prescribed medications and treatment plans. Communication: Difficulty in expressing needs and understanding instructions, affecting overall health management. Safety Concerns: Increased vulnerability to accidents, falls, and emergencies.

Production 52

Production Treatment Disease Marketing 52

The Pharma Data

JANUARY 18, 2021

. Experienced executive development team from Gilead Sciences. a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases, today announced its launch backed by $80 million Series C financing led by Abingworth LLP. SOUTH SAN FRANCISCO, Calif. ,

Disease 52

Disease Science Clinical Development Treatment 52

The Pharma Data

DECEMBER 8, 2020

The company’s commercial priorities are three-fold: (1) Initially focusing its commercial efforts on rare diseases within its prolific neurology and cardiology franchises (2) pioneer new markets where there are no available treatments (3) create new standards of care where there has been a lack of innovation to optimize patient care.

RNA 52

RNA Pharmaceuticals Disease Production 52

The Pharma Data

DECEMBER 28, 2020

Scopus is a biopharmaceutical company whose lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. Dr. Russell has managed all aspects of the drug development and regulatory approval processes for oncology and non-oncology drug candidates. from the Harvard T.H.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Government Therapies 52

Perficient: Drug Development

NOVEMBER 7, 2023

But, occasionally, you’ll want to motivate users to fill out a form, download an e-book, sign up for a seminar or any number of other related activities. Make it easy for them to verify your claims no matter how they’re interacting with you. Most of your content across all platforms and experiences should encourage a conversion.

Therapies 52

Therapies Treatment Production Marketing 52

Perficient: Drug Development

JUNE 27, 2023

Lack of accessible healthcare facilities, limited availability of specialized equipment or treatments, and inadequate training of healthcare professionals in disability-specific care can pose significant challenges to individuals seeking medical assistance.

Production 52

Production Treatment Disease Marketing 52

The Pharma Data

DECEMBER 22, 2020

“This trial is part of our commitment to develop ASP-1929 as part of our proprietary Illuminox platform for advancing treatment in HNSCC, as well as expanding into CuSCC,” said Hiroshi Mikitani, Chairman and CEO of Rakuten Medical. View original content to download multimedia: [link]. SOURCE Rakuten Medical, Inc.

Clinical Trials 52

Clinical Trials Therapies Trials Production 52

The Pharma Data

JANUARY 7, 2021

RMI), a global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox , will present at the 39th Annual J.P. has been using an exclusively licensed antibody complex to develop new cancer therapies based on its Illuminox TM technology platform.

Clinical Trials 52

Clinical Trials Therapies Trials Licensing 52

Perficient: Drug Development

JULY 3, 2023

By focusing on social barriers, it may undermine the significance of medical interventions, treatments, and assistive technologies that can enhance the quality of life and functioning for individuals with disabilities.

Production 52

Production Treatment 52

Perficient: Drug Development

JULY 7, 2023

This imbalance can lead to a lack of attention to medical interventions and treatments that may be necessary for individuals with certain conditions. Critics argue that the model should strike a better balance and give due consideration to all three dimensions.

Production 52

Production Treatment 52

The Pharma Data

SEPTEMBER 17, 2020

Lilly is currently studying several potential neutralizing antibodies for the prevention and/or treatment of COVID-19 as either monotherapy or in combination. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. Source link.

Therapies 52

Therapies Production Government Disease 52

The Pharma Data

JANUARY 13, 2021

Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of Brilacidin as a potential treatment for COVID-19. A molecular screening study of 11,552 compounds also supports Brilacidin as a promising novel coronavirus treatment. WAKEFIELD, Mass.,

Clinical Trials 52

Clinical Trials Trials Treatment FDA 52

PPD

NOVEMBER 21, 2023

The drug development industry is constantly adapting and evolving to bring novel therapeutics to market to improve the lives of patients across the globe. While the drug development industry experienced setbacks during the COVID-19 pandemic, the field  is again gaining momentum reminiscent of its pre-pandemic pace.

Clinical Development 52

Clinical Development Clinical Trials Trials Clinical Research 52

Conversations in Drug Development Trends

JUNE 13, 2024

Pharmacogenomics (PGx), the study of how genes affect a person’s response to drugs, has brought significant changes to the clinical trial industry. This groundbreaking approach can help tailor medical treatments to an individual’s genetic makeup, considerably enhancing drug efficacy and safety while minimizing adverse drug reactions.

DNA 72

DNA Compliance Clinical Trials Trials 72

The Pharma Data

JANUARY 25, 2021

26, 2021 /PRNewswire/ — Dynacure , a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today that the U.S. DYN101 has been granted Orphan Drug designations by the U.S. ” The U.S.

Treatment 52

Treatment Disease Pharmaceuticals FDA 52

The Pharma Data

NOVEMBER 1, 2020

Corlieve is focused on developing novel therapeutics for severe neurological disorders. Corlieve’s lead program employs a novel AAV gene therapy approach for the treatment of refractory temporal lobe epilepsy (TLE), the most commonly diagnosed focal epilepsy in humans. View original content to download multimedia: [link].

Therapies 52

Therapies Science Treatment Disease 52

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 118

Therapies DNA Virus Clinical Trials 118

The Pharma Data

OCTOBER 14, 2020

. “We are very pleased that the FDA has cleared our IND, and we plan to initiate clinical development of AP-PA02 by the end of this year, consistent with our original guidance notwithstanding disruptions to drug development timelines across the industry caused by the COVID-19 pandemic,” stated Todd R.

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Drugs 52

The Pharma Data

JANUARY 26, 2021

. Armata intends to use the net proceeds for the ongoing advancement of its bacteriophage development programs, including its FDA cleared first-in-human study, SWARM- P.a. Phase 1b /2a clinical trial evaluating AP-PA02 as a potential treatment for Pseudomonas aeruginosa infections in the coming months.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Production 52